In Sun et al.’s study, Oxamate as a lactate dehydrogenase A (LDHA) inhibitor, which has been found to reduce the lactic acidification of histone H3K18, thereby changing the phenotype of immune molecules, promoting the immune activation of tumor-infiltrated CAR-T cells and reducing the immunosuppression of the TME (95). The gene discussed is LDHA; the disease is neoplasm.